The most frequent application of any dosimetry, i.e., responses in the Always/Majority category either as part of treatment planning or on a post-therapy basis (Fig. 2), was reported for 177Lu-PSMA (100%), 90Y microspheres of glass (84%) and resin (82%), 131I-mIBG for neuroblastoma (59%), and 131I-NaI for benign thyroid diseases (54%). The gene discussed is FOLH1; the disease is neuroblastoma.